How does retatrutide compare to current GLP-1 drugs?

Retatrutide surpasses the 30% weight loss threshold, higher than current drugs like Ozempic and Wegovy which achieve around 15-20%.

When will retatrutide be available?

Eli Lilly has not announced a launch date; the drug is still in clinical development.

Eli Lilly's Retatrutide Surpasses 30% Weight Loss Ceiling

Eli Lilly's retatrutide has crossed the 30% weight loss threshold in some patients, positioning it as a potential leader in the obesity drug market.

July 1, 2026

2 min read

Source: Pharmaceutical Technology

Key Numbers

weight loss percentage

30%

Eli Lilly (ticker: LLY) announced promising results for its experimental drug retatrutide, which achieved over 30% weight loss in some patients in clinical trials. This milestone places the drug ahead of existing GLP-1RA treatments for obesity.

The Product

Retatrutide is an experimental GLP-1RA that stimulates GLP-1 receptors to boost insulin secretion and reduce appetite. Its key differentiator is the ability to achieve greater weight loss compared to current drugs like Ozempic and Wegovy.

Pricing and Availability

Eli Lilly has not yet disclosed pricing or a launch timeline. The drug will likely undergo regulatory review before commercialization.

Competition

Retatrutide faces competition from other GLP-1RAs such as semaglutide from Novo Nordisk. However, surpassing the 30% weight loss benchmark could give it a competitive edge in the growing obesity market.

Potential Impact on the Company

If approved, retatrutide could significantly boost Eli Lilly's revenue and expand its share in the multibillion-dollar obesity drug market.

Frequently Asked Questions

Retatrutide is an experimental GLP-1RA drug developed by Eli Lilly for obesity, achieving over 30% weight loss in some patients.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.